Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | PSMD10 | O75832 | 1/20 | 0.39 |
| ▸ | CYP24A1 | Q07973 | 2/20 | 0.38 |
| ▸ | STAT3 | P40763 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | G6PD | P11413 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | VDR | P11473 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA3 | P07451 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21149355 | 0.98 | CA12 (0.39) | CA12CA1CA9ALDH1A1CYP3A4 | |
| SCHEMBL1016953 | 0.98 | CA12 (0.39) | CA12CA1CA9ALDH1A1CYP3A4 | |
| SCHEMBL1016996 | 0.98 | CA12 (0.39) | CA12CA1CA9ALDH1A1CYP3A4 | |
| SCHEMBL23015111 | 0.98 | CA12 (0.39) | CA12CA1CA9ALDH1A1CYP3A4 | |
| SCHEMBL8926866 | 0.98 | CA12 (0.39) | CA12CA1CA9ALDH1A1CYP3A4 | |
| SCHEMBL25362116 | 0.98 | CA12 (0.39) | CA12CA1CA9ALDH1A1CYP3A4 | |
| SCHEMBL23832592 | 0.98 | CA12 (0.39) | CA12CA1CA9ALDH1A1CYP3A4 | |
| SCHEMBL25371249 | 0.98 | CA12 (0.39) | CA12CA1CA9ALDH1A1CYP3A4 | |
| SCHEMBL278880 | 0.95 | ALDH1A1 (0.41) | CA12CA1CA9ALDH1A1CYP3A4 | |
| SCHEMBL31173815 | 0.91 | ALDH1A1 (0.40) | CA12CA1CA9ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-56071059-A | — | — | None | — | — | JP | disclosed |
| US-12624044-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4731309-A1 | KRAS PROTEOLYSIS TARGETING CHIMERAS | Paq Therapeutics Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| WO-2025262297-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| WO-2025262295-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| EP-4667467-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2025-12-24 | — | — | EP | disclosed |
| EP-4667466-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2025-12-24 | — | — | EP | disclosed |
| US-12404285-B2 | KRAS G12D proteolysis targeting chimeras | PAQ Therapeutics Inc. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250154157-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR TREATING A ERK5-MEDIATED DISEASE | CANCER RESEARCH TECH LTD (GB) | 2025-05-15 | — | — | US | disclosed |
| EP-4519273-A1 | KRAS G12D PROTEOLYSIS TARGETING CHIMERAS | Paq Therapeutics Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| EP-0313697-A1 | Leukotriene antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1989-05-03 | — | — | EP | disclosed |
| US-4820719-A | ANTIALLERGENS, ANTIINFLAMMATORY, ANTIISCHEMIC AND HYPOTENSIVE AGENTS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-04-11 | — | — | US | disclosed |
| EP-0296731-A1 | Leukotriene antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1988-12-28 | — | — | EP | disclosed |
| EP-0296732-A1 | Leukotriene antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1988-12-28 | — | — | EP | disclosed |
| US-4730005-A | DITHIA-ALKANEDIOIC ACIDS | SMITHKLINE BECKMAN CORPORATION (US) | 1988-03-08 | — | — | US | disclosed |
| EP-0168902-B1 | LEUKOTRIENE ANTAGONISTS | SMITHKLINE BECKMAN CORPORATION (US) | 1987-09-30 | — | — | EP | disclosed |
| EP-0202759-A2 | Leukotriene antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1986-11-26 | — | — | EP | disclosed |
| EP-0168902-A1 | Leukotriene antagonists | SMITHKLINE BECKMAN CORPORATION (US) | 1986-01-22 | — | — | EP | disclosed |
| JP-S5671059-A | 1-SULFONYLOXY-5-HEXYNE DERIVATIVE AND ITS PREPARATION | SAGAMI CHEM RES CENTER | 1981-06-13 | — | — | JP | disclosed |
| US-4064257-A | Thiazole cardiovascular agents | SYNTEX (U.S.A.) INC. (US) | 1977-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404285-B2 | KRAS G12D proteolysis targeting chimeras | KRAS, NRAS, HRAS | CA12 1664/4885CA1 1263/4885CA9 735/4885 |
| US-12624044-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCC1, SMARCA2 | CA12 3603/4885CA1 2045/4885CA9 3592/4885 |
| US-20250154157-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR TREATING A ERK5-MEDIATED DISEASE | MAP3K5, MAPK1, MAP3K20 | CA12 4638/4885CA1 4617/4885CA9 4443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.